Doree to lead US sales of stomach cancer breath test
This article was originally published in Clinica
Exalenz Bioscience is forging ahead with the US commercialization of its BreathID Hp breath test for managing gastrointestinal conditions, having appointed a new vice-president of sales, Gavin Doree, to lead the charge. Mr Doree will head the company’s newly established direct sales organization in the US, based in New Jersey. His appointment coincides with the worldwide launch of the second-generation BreathID Hp device, which uses the real-time, continuous breath of the patient to detect the presence of the H pylori bacteria associated with various illnesses including peptic ulcers and stomach cancer. Prior to joining Israel-headquartered Exalenz, Mr Doree was national director and director of strategic accounts at Medivators, a Minneapolis, Minnesota specialist in infection prevention technologies.